Teva In-Focus: A New Webinar Series For The Investment Community Focusing On Teva’s R&D Activities

In an effort to keep our shareholders and analysts informed and up to date on the progress of our promising R&D programs, we are launching Teva In-Focus .

This new webinar series provides an in-depth view of Teva’s R&D strategies and progress in primary therapeutic areas in a format that is focused, detailed, and accessible.

Teva In-Focus kicks off on Tuesday, October 8 th at 8:00am Eastern Time with a focus on our Respiratory franchise, providing insight into Teva’s commercial and R&D franchise as well as our strategy for building a leadership position in respiratory therapies.

Teva In-Focus will include a review of the global market and unmet needs, our approach to innovation and therapeutic development, and a deep dive into key projects that we believe will drive Teva’s future growth in the respiratory market.

Dr. Michael Hayden, Teva’s President of Global R&D and Chief Scientific Officer, will lead the webinar and will be joined by Teva’s respiratory franchise leadership including Hans Luijendijk, Head of Global Respiratory Marketing, Global Specialty Medicine Group and Dr. Tushar Shah, Global Respiratory R&D, Teva Global R&D.

A question and answer session will follow the presentation.

Webinar access details:
 

Meeting Title:
  Teva Respiratory Webinar

Meeting Date:
October 08, 2013

Meeting Time:
08:00 AM [Eastern Time]

Duration:
1 Hour 30 Minutes
 

Webcast Link:

http://www.media-server.com/m/p/uirw5j42
 

Dial-in details:
 

1 (800) 303-0442
US Toll Free

1 (847) 413-3733
International
 

Confirmation Number:
35785039

About Teva

Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) is a leading global pharmaceutical company, committed to increasing access to high-quality healthcare by developing, producing and marketing affordable generic drugs as well as innovative and specialty pharmaceuticals and active pharmaceutical ingredients. Headquartered in Israel, Teva is the world's leading generic drug maker, with a global product portfolio of more than 1,000 molecules and a direct presence in about 60 countries. Teva's branded businesses focus on CNS, oncology, pain, respiratory and women's health therapeutic areas as well as biologics. Teva currently employs approximately 46,000 people around the world and reached $20.3 billion in net revenues in 2012.

If you liked this article you might like

S&P 500 and Dow Score Records With Wall Street Upbeat Ahead of Fed

S&P 500 and Dow on Track for Records With Markets in Good Mood Ahead of Fed

S&P 500 and Dow Aim for New Records With Broad-Based Gains Ahead of Fed

Dow and S&P 500 Reach New Intraday Highs With Markets in Good Mood Ahead of Fed

Teva's New CEO Brings This Secret Weapon